Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
November 09 2021 - 8:00AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that Dr. Steven O’Day, Chief Medical
Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug
Discovery at Agenus, will participate in a fireside chat hosted by
B. Riley on Monday, November 15, 2021 at 12:00 PM EST. Dr. O’Day
and Dr. Chand will discuss the AGEN1181 program (Fc-enhanced
CTLA-4), following presentation of clinical data at the Society for
Immunotherapy of Cancer (SITC) 36th Annual Meeting on Friday,
November 12th, 2021.
Registration for the webinar can be done in advance
at: https://www.webcaster4.com/Webcast/Page/2433/43588.
A replay will be available after the call on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its affiliate MiNK Therapeutics), adjuvants, and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of therapeutic candidates AGEN 1181,
for instance, statements regarding therapeutic benefit and
efficacy, mechanism of action, potency, durability, and safety
profile of the therapeutic candidates, both alone and in
combination with each other and/or other agents; future clinical
and regulatory development plans for AGEN1181; and any other
statements containing the words "may," "believes," "expects,"
"anticipates," "hopes," "intends," "plans," "will" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
ContactAgenus Inc.Divya
Vasudevan, PhD781-674-4571divya.vasudevan@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024